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The long-term course (mean 15 years) of 336 patients
with valvular incompetence who underwent Starr-
Edwards ball valve implantation between 1962 and 1971
was reviewed. Eighteen patients (10%) with aortic valve
replacement and 24 (16%) with mitral valve replacement
died early postoperatively. Mortality remained high (31 %)
in the first 3 years after aortic valve replacement; it was
highest (13%) in the first year after mitral valve re-
placement and then approached the normal rate. The
most common mode of death was sudden death after
aortic and cardiac failure after mitral valve replacement.
Patients with left ventricular volume overload due to aortic
or mitral valve incompetence have a distinctive natural his-
tory and prognosis (I). The frequently prolonged course and
lack of correlation between hemodynamic variables and
clinical deterioration in patients with valvular incompetence
have made decisions for proper operative timing difficult
and imprecise (2).
Between 1962 and 1971, the Starr-Edwards caged-ball
prosthesis was by far the most preferred replacement valve
at the Mayo Clinic. With use of the caged-ball valve pros-
thesis now in its third decade, evaluation of the long-term
outcome of valve replacement in specific groups of patients
is appropriate. Accordingly, we report the long-term course
of all patients with severely symptomatic isolated aortic or
mitral valve incompetence who underwent implantation of
a Starr-Edwards caged-ball prosthetic valve at the Mayo
Clinic between 1962 and 1971. Factors evaluated include
survival and symptomatic results of operation, causes and
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At follow-up, 76% of survivors had improved symp-
tomatically. Three instances of primary valve malfunc-
tion occurred. The probability of freedom from throm-
boembolism at 15 years postoperatively was 56% for
aortic valve replacement and 52% for mitral valve re-
placement. The Starr-Edwards valve prothesis is du-
rable over prolonged follow-up period, but thromboem-
bolism remains a persistent problem. Survival may be
normal for patients surviving the early postoperative
years.
predictors of early and late mortality and occurrence and
prediction of thromboembolic complications.
Methods
Selection criteria. Patients were included in the study
if, on retrospective review of their medical chart, the fol-
lowing criteria were fulfilled: I) isolated or predominant
aortic or mitral incompetence was present as determined
from the physical examination or cardiac catheterization, 2)
symptoms of New York Heart Association functional class
III or IV severity were present before valve replacement,
and 3) a Starr-Edwards caged-ball prosthesis was implanted
between 1962 and December 1971. Specifically excluded
from analysis were patients with evidence of mixed valvular
incompetence and stenosis or multivalvular involvement,
clinically suspected or angiographically documented coro-
nary artery disease or congenital cardiac lesions, prior car-
diac operation of any type or potentially fatal noncardiac
disease.
All patients were under surveillance until January 1981;
the total follow-up period ranged from 10 to 19 years (mean
15). Follow-up information was obtained from examinations
at the Mayo Clinic or from responses to letters or telephone
calls to the patients, their relatives and referring physicians.
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Age (yr)
Mean 49 52
Range 17 to 75 14 to 74
Sex (%)
Female 16 44
Male 84 56
NYHA functional class (%)
III 86 85
IV 14 15
Cardiomegaly
(by chest roentgenogram) (%)
None to mild 17 12
Moderate to severe 83 88
Atrial fibrillation (%) 22 67
Left ventricular hypertrophy 87 4\
(by electrocardiogram) (%)
Cause (%)
Rheumatic disease 53 61
Infective endocarditis 20 3
Congenital anomaly 9 0
Syphilis 3
Ruptured chordae 22
Other 4 0
Unknown II 14
NYHA = New York Heart Association.
The occurrence of thromboembolic events (such as a
stroke with a time course consistent with embolism, un-
expected myocardial infarction, sudden ischemia of a limb
or retinal artery embolus) was determined on the basis of
historical or invasive evaluation.
Study group. Between January 1962 and December 1971,
5,956 patients with a diagnosis of aortic valve incompetence
and 4,085 patients with a diagnosis of mitral valve incom-
petence were examined at the Mayo Clinic. During this
period, 1,027 aortic Starr-Edwards valves were implanted,
274 for isolated aortic valve incompet~nce, and 657 mitral
Starr-Edwards valves were implanted, 220 for isolated mi-
tral valve incompetence. The inclusion criteria were fulfilled
in 189 and 147 of these cases, respectively. Most exclusions
of patients who underwent operation were determined on
the basis of the presence of significant associated valvular
or coronary artery disease or a history of a prior cardiac
surgical procedure. Twenty-five patients with aortic valve
replacement and six patients with mitral valve replacement
were excluded because they were in functional class 11 or
asymptomatic. In addition, 12 patients with aortic valve
replacement and 7 with mitral valve replacement were lost
to follow-up after operation and are not included. All re-
maining patients were followed up until death or 1981.
The groups were similar with respect to age, functional
classification and degree of cardiomegaly (Table I). Male
Table 1. Characteristics of Patients
Aortic Incompetence
(n = 189)
Mitral Incompetence
(n = 147)
patients predominated, especially in the aortic valve group
(84 versus 56% in the mitral valve group). Etiologic clas-
sification was made on the basis of clinical impression and
the gross description at the time of operation; valve distor-
tion secondary to presumed chronic rheumatic valvulitis was
the most common cause.
Surgical procedures. During the decade of the study
period, the techniques of the operation, extracorporeal cir-
culation and myocardial protection evolved rapidly. Thus,
analysis of subgroups on the basis of such variables was
impractical. Generally, however, the procedures were con-
ducted with use of moderate hypothermia (30°C), high flow
(2.0 liters/min per m2) extracorporeal circulation, continu-
ous right and left coronary artery perfusion for aortic valve
replacement and intermittent (15 to 20 minute periods) aortic
cross clamping for mitral valve replacement.
Among patients who underwent aortic valve replace-
ment, 43% received a Starr-Edwards pre-I 000 or 1000 series
caged-ball prosthetic valve, 41 % received a 1200 series
valve and 16% received a 1260 series valve. Patients who
underwent mitral valve replacement received a Starr-Ed-
wards 6000 (42%),6120 (48%) or 6310 (10%) series valve.
The 1000 series aortic valves were implanted until 1966,
and the 6000 series mitral valves were inserted until 1965.
The 1200 and 1260 aortic prostheses and the 6120 and 63 10
mitral prostheses were used subsequent to those dates.
Adequacy of anticoagulation. After valve replacement,
anticoagulant agents were given to all patients except 10 in
whom anticoagulant therapy was contraindicated (7 with an
aortic and 3 with a mitral prosthesis). Assessment of ade-
quacy of anticoagulation was difficult and hampered by
incomplete follow-up information. At least one prothrombin
time determination per year was available for \, \46 patient-
years (42%) of the total 2,696 patient-years of follow-up.
As described previously (3), if more than one prothrombin
time determination was available for a calendar year, the
mean value was taken as representative of that year. When
a thromboembolus occurred, the mean prothrombin time for
that calendar year preceding the event was used because,
after the event, anticoagulation was usually more strictly
maintained in a precise therapeutic range. Anticoagulation
was defined as adequate when the prothrombin time was at
least \.5 times the control value.
Statistical analysis. The significance in univariate anal-
ysis of prognostic factors was tested with Student's t test
or the chi-square test. Stepwise linear discriminant function
analysis was carried out according to the BMD-P7M com-
puter program of the Health Sciences Computing Facility,
University of California, Los Angeles, California.
Results
Early mortality. Eighteen patients (10%) with aortic
valve replacement and 24 patients (16%) with mitral valve
replacement died within 30 days after operation. Of all
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Table 2. Factors Associated With Early Mortality After
Starr-Edwards Aortic Valve Implantation (1963 to 1971)*
NYHA Death Survival
Functional :s30 Days >30 Days Early Death
Class (n = 18) (n = 171) (%)
III 10 152 62}
P < 0.001
IV 8 19 29.6
*Factors that proved not significant were age, sex, degree of cardio-
megaly, presence of atrial fibrillation, left ventricular hypertrophy, valve
model implanted and date of operation. NYHA = New York Heart As-
sociation; p = probability.
variables analyzed, only functional disability was associated
significantly (probability [p] < 0.00 1) with early mortality
in patients with aortic valve replacement (Table 2). In pa-
tients with mitral valve replacement (Table 3), those vari-
ables significantly associated with early mortality were class
IV functional status (p < 0.001), implantation of a 6000 or
6310 series valve (p < O. 00 I) or operation performed during
the first half of the study period (p < 0.05).
The causes ofearly death in each group are summarized
in Figure IA. Early deaths in patients with mitral valve
replacement were most frequently attributable to left ven-
tricular failure (38%) or arrhythmia (29%). Nonsurvivors
in the aortic valve replacement group were more evenly
distributed among the various causes of death, including
inability to wean from cardiopulmonary bypass, embolic
events, infectious complications, hemorrhage and aortic
dissection.
Late mortality. Actuarial survival curves for patients
who survived the 30 day postoperative period are presented
in Figures 2 and 3. For patients who received an aortic
valve, the mortality rate was highest in the first year (16%
died), and it remained relatively high for the first 3 years,
at which point actuarial survival was 69%. After 3 years,
the mortality rate declined until the sixth year, when it
stabilized at the same rate as that of an age- and sex-matcheq
general population for the duration of follow-up. The 15
year actuarial survival was 40%.
Patients with a mitral valve prosthesis (Fig. 3) also had
a high first year mortality rate (13%). Although mortality
subsequently declined, it remained somewhat higher than
the expected mortality rate for the overall follow-up period.
The 15 year actuarial survival rate was 38%.
Causes of late death for the 105 patients with aortic and
69 patients with mitral valve replacement who died during
long-term follow-up are depicted in Figure 1B. The pre-
dominant mode of death among those with an aortic valve
prosthesis was sudden death (27%); in those with a mitral
valve prosthesis, it was left ventricular failure (29%). These
were followed by deaths due to myocardial infarction and
other embolic events in both groups.
Clinical variables predictive of late mortality were ex-
amined in the 30 day survivors; these factors included age,
sex, functional classification, heart size, presence of atrial
fibrillation, duration of known valve disease, duration of
symptoms, valve model implanted and date of operation.
When considered separately, age and male sex were asso-
ciated (p < 0.05) with late mortality in patients with an
aortic valve prosthesis, as were age, male sex and functional
status in patients with a mitral valve prosthesis.
When all variables were considered in a multivariate
fashion using a stepwise proportional hazards model, age
and male sex in patients with an aortic valve prosthesis and
age and functional status in those with a mitral valve pros-
thesis remained significantly (p < 0.05) associated with late
mortality.
Valve durability. Twelve patients with an aortic valve
prosthesis experienced problems related to the prosthesis.
Six of these complications resulted in late death (Fig. IB);
Table 3. Factors Associated With Early Mortality After Starr-Edwards Mitral Valve Implantation (1962 to 1971)*
Death :s30 Days Survival>30 Days Early Death
Factor (n = 24) (n = 123) (6)
NYHA functional class
III 10 116 7O}
P < 0.001
IV 14 7 66.7
Valve model
6000 18 43 29.5}
6120 3 68 4.2 P < 0.001
6310 3 12 20.0
Date of operation
1962 to 1966 16 51 23.9}
P < 0.05
1967 to 1971 8 72 10.0
*Factors that proved not significant were age, sex, degree of cardiomegaly, presence of atrial fibrillation and left ventricular hypertrophy. NYHA =
New York Hearl Association.
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Figure 1. Causes of (A) early postoperative mortality (death within
30 days after Starr-Edwards valve implantation) and (8) late
mortality.
five deaths were attributed to paravalvular leak or dehiscence
(three series pre-1000 or 1000, one series 1200 and one
series 1260), and one was due to valve thrombosis (series
1260), Six patients underwent successful reoperation for
valve-related problems: five for paravalvular leak or dehis-
cence (four series pre-1000 or 1000 and one series 1260)
and one for ball variance (model 1000),
Seven patients with mitral valve replacement had late
valve-related complications, and one patient died as a con-
sequence, In this patient, valve dehiscence of a model 6120
valve was clinically suspected but autopsy was not per-
formed, The remaining patients underwent reoperation: five
for paravalvular leak or dehiscence (one series 6000, two
series 6120 and two series 6310) and one for ball variance
(model 6000).
Thromboembolism. Actuarial probability of survival
free of thromboembolic events with aortic or mitral valve
replacement is shown in Figure 4. The occurrence of first
thromboembolic events followed a similar time course in
both groups. At 5 years postoperatively, 74% of survivors
in the aortic valve replacement group and 72% of survivors
in the mitral valve replacement group were free of throm-
boembolism. At 10 years 62 and 60% and at 15 years 56
and 52%. respectively. remained free of thromboembolism.
Seventeen percent of patients with an aortic valve prosthesis
and 28% of patients with a mitral valve prosthesis had two
or more thromboembolic events.
Cerebral embolism. More than 80% of clinically appar-
ent emboli entered the cerebral circulation. and only several
went to either the coronary or the peripheral arteries. No
significant difference in location of emboli was noted be-
tween patients with aortic and those with mitral prostheses
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Figure 2. Actuarial survival of patients with iso-
lated Starr-Edwards aortic valve replacement (AVR)
for symptomatic aortic incompetence. A, Entire
group. B, By valve model implanted. Hospital deaths
are excluded. Number of survivors at each time
interval is shown below the horizontal axis. The
expected survival. determined on the basis of age
and sex distribution, is from the 1970 life table for
the west north central states.
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Figure 3. Actuarial survival of patients with iso-
lated Starr-Edwards mitral valve replacement
(MVR) for symptomatic mitral incompetence. A,
Entire group. B, By valve model implanted; the
6310 series is not depicted because of small sam-
ple size. Hospital deaths are excluded. Number
of survivors at each time interval is shown below
the horizontal axis. The expected survival, deter-
mined on the basis of age and sex distribution, is
from the 1970 life table for the west north central
states.
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Years
6000 61 29 27 23 20 18 17 16 16 15 15
6120 and 6310 66 72 68 67 58 51 46 42 38 27 21
As preoperative assessment and operative techniques have
been refined, indications for surgical intervention may have
liberalized and otherwise changed, so that a different and
broader group of patients may be undergoing valve replace-
ment now as compared with 20 years ago, Despite these
modifications, there is a compelling need for reporting the
long-term outcome of patients undergoing valve replace-
ment. This is a report of the long-term course of patients
who received a Starr-Edwards caged-ball valve for man-
agement of aortic or mitral valve incompetence, 8y limiting
this study population to a relatively homogeneous group of
severely symptomatic patients who had valvular incompet-
ence, these results are applicable to the difficult decisions
frequently encountered in this type of patient.
Early mortality. In these patients, we observed a sub-
stantial postoperative mortality (16% for mitral valve re-
placement and 10% for aortic valve replacement), These
results are similar to those previously reported (4-19), which
range from 0 to 17% for all patients who have undergone
aortic valve replacement and 5 to 20% for those who have
undergone mitral valve replacement. The operative mortal-
ity rate for patients with regurgitant lesions has been gen-
erally higher (7 to 20% for mitral valve replacement and
approximately 17% for aortic valve replacement) (11,12,15)
Discussion
type were shown to be independent and significant predis-
posing factors,
Status of' anticoagulation, During follow-up, the status
of anticoagulation was known for 1,146 patient years, Pa-
tients were adequately anticoagulated during 74% of those
years, In patients with an aortic valve prosthesis, the number
of embolic events per 100 patient years was 6,5 in the group
with adequate anticoagulation and 8,5 in the group with
inadequate anticoagulation (Table 5); the difference did not
reach statistical significance, In patients with mitral valve
replacement, the number of embolic events per 100 patient
years was 6.4 in the group with adequate anticoagulation
and 14,2 in the group with inadequate anticoagulation (p <
0,01; Table 5),
No significant difference was observed in survival free
of thromboembolism among the aortic valve types (Fig, 48),
Among patients with a mitral valve prosthesis, however,
the rate of survival free of thromboembolism in the group
with 6000 series valves was lower than in the group with
6120 or 6310 series valves (p < 0,02; Fig. 4C),
Symptomatic status. The majority (80%) of patients
with aortic valve replacement who were alive at the time
of follow-up had improved symptomatically by at least one
functional class (Fig, SA), Of surviving patients with mitral
valve replacement, 72% had experienced a similar degree
of improvement (Fig, 58), Overall, 76% of long-term sur-
vivors had benefited and 33% had become asymptomatic.
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(Table 4), Fifty percent of the cerebral embolic events re-
sulted in permanent neurologic sequelae, and I in 10 was
fatal (Table 4),
Predisposing factors, Of the possible factors predispos-
ing to thromboembolism that were evaluated-age, sex,
atrial fibrillation, degree of cardiomegaly, history of pre-
operative embolism, presence of left atrial thrombus at the
time of operation, adequacy of anticoagulation and valve
type-only the adequacy of anticoagulation and the valve
Figure 4. Probability of survival free of thromboembolism plotted
against time in years in patients with (A) isolated Starr-Edwards
aortic valve replacement (AVR) or mitral valve replacement (MVR):
(B) different models of aortic prostheses: and (el different models
of mitral prostheses. Number of surviving patients free of throm-
boembolism at each interval is shown below the horizontal axis.
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Table 4. Location and Effect of Systemic Thromboembolism
Location
Cerebral
Peripheral artery
Coronary
Residual
Emboli (%) Deficit (%) Death (%)
AVR MVR AVR MVR AVR MVR
84 86 57 48 10 11
6 10 3 0 0 0
10 4 4 4 0 0
100% 100%
(40 emboli) (47 emboli)
AVR = aortic valve replacement; MVR mitral valve replacement. Reproduced from Fuster et al. (22) by permisson of the American Heart
Association, Inc.
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Figure 5. Current functional class of patients who underwent iso-
lated Starr-Edwards aortic valve (A) or mitral valve (B) replace-
ment. Figures in parentheses indicate number of patients in each
preoperative functional class who are currently living.
Present Functional
Class
I
Despite the lack of controlled trials, the survival curve
for disabled patients who have undergone surgical replace-
ment of incompetent valves seems to show definite im-
provement over the survival rates of comparable patients
without operation (3,8,10,20). The actuarial survival of our
patients was comparable with that of patients with aortic or
mitral valve replacement in other long-term studies (9,21).
Valve durability. This study confirms that the func-
tional durability of the Starr-Edwards prosthesis is remark-
ably high. Sixteen patients had a paravalvular leak or de-
hiscence, but only three patients experienced complications
that may be attributed to primary malfunction of the valve
apparatus. Only one of these complications (valve throm-
bosis) was fatal, whereas the other two patients (with ball
variance) were successfully managed with reoperation. The
rare and sporadic occurrence of valve malfunction in this
Table 5. Role of Adequacy of Anticoagulation in
Thromboembolism •
than for those with nonregurgitant lesions of the same valve.
In the present study, advanced functional disability was
significantly associated with early postoperative mortality.
This finding probably reflects more hemodynamic compro-
mise, higher likelihood of irreversible myocardial damage
and greater need for urgency of operation. As in previous
reports (4,18), operative mortality rate decreased as surgical
experience accrued, though this improvement was statisti-
cally significant only for mitral valve replacement.
Late mortality. We observed a relatively high mortality
rate in the early period after discharge of survivors from the
hospital. This high rate was most apparent during the first
3 years in patients with aortic valve replacement (average
1O.3%/yr) and for the first year in patients with a prosthetic
mitral valve (13%). Deaths during this period probably are
a result of a technically imperfect operative result, advanced
and irreversible myocardial damage or severe associated
disease such as undiagnosed coronary atherosclerosis or a
conduction defect.
After the high mortality rate of the early postoperative
years, the rate declined in both groups of patients and ap-
proached (in the mitral valve group) or approximated (in
the aortic valve group) the expected rate for a comparable
normal population. It seems reasonable to assume that pa-
tients surviving the first year or years after operation may
have undergone operation before the occurrence of irrever-
sible or advanced myocardial damage.
NS = not significant. Reproduced from Fuster et al. (22) by permission
of the American Heart Association, Inc.
Adequate Inadequate Adequate Inadequate
Number of emboli 30 17 25 15
Patient years 466 120 383 177
Emboli per 100 6.4 14.2 6.5 8.5
patient years
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Aortic Prosthesis
Anticoagulation
p < 0.01
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large patient group is particularly notable in view of the
substantial proportion of reported complications among pa-
tients with early models of prostheses that have since been
discontinued.
Thromboembolism. The thromboembolic consequences
of prosthetic valves in these patients have been described
previously in detail (22). Obviously, thromboembolism is
a major factor in the mortality and morbidity of patients
with valve replacement: by 15 years after operation, almost
50% sustained a systemic embolic event. The rate of sys-
temic embolism is similar for valve prostheses at mitral and
aortic sites.
Mitral versus aortic prostheses. An adequate status of
anticoagulation seems to reduce the risk of systemic em-
bolism significantly only in patients with a mitral valve
prosthesis. This finding may indicate a difference in the
pathogenesis of emboli originating from mitral and aortic
valve prostheses (22). A thrombus in relation to a mitral
valve prosthesis is usually located in the left atrium and
around the sewing ring, with the red cell-fibrin appearance
of a venous thrombosis (23); therefore, it is reasonable to
expect that oral anticoagulants, which prevent formation of
fibrin when given in an adequate dose, may have a protective
effect. In contradistinction, the high blood flow across an
aortic prosthesis may predispose to emboli that consist pre-
dominantly of platelets (24,25); in such cases, the addition
of platelet-inhibitor agents may be more beneficial (26-31).
Old versus recent valve models. The higher incidence
of systemic thromboembolism in patients with a 6000 series
mitral valve prosthesis is probably due in part to the throm-
bogenicity of the metal surface of the valve ring, which was
subsequently reduced in later models. The incidence of
thromboembolic events in patients with the 1000 series aor-
tic prosthesis was not significantly higher than in those with
more recent models. This finding may again indicate a dif-
ference in the pathogenesis of thromboembolism between
mitral and aortic Starr-Edwards prostheses, thromboem-
bolism from the latter being less dependent on valve design.
Symptomatic status. Most long-term survivors expe-
rience a definite and sustained improvement in symptoms,
which is still maintained at a minimum of 10 years after
valve replacement. The success of operation in alleviating
symptoms is in itself a valid indication for valve replace-
ment. The symptomatic benefit in these patients further em-
phasizes the need for defining the optimal time for inter-
vention and suggests that, although postponing a surgical
procedure may increase risks, the development of symptoms
does not necessarily imply that results will be inadequate
with regard to either survival or symptomatic improvement.
Conclusion. Starr-Edwards caged-ball valves (both out-
dated and currently used models) are highly durable prostheses
that afford substantially improved long-term survival and
symptomatic relief to seriously compromised patients with
aortic or mitral valve incompetence. Beneficial effects are
most apparent in those patients who survive the early post-
operative period, after which life expectancy seems to ap-
proach normal levels. Despite these advantages, systemic
thromboembolism remains a persistent problem throughout
the follow-up period.
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